Why Cancer Treatments Stop Working For So Many Patients

IV drip in a hospital corridor with a blurred background

Your immune system’s cancer-fighting cells carry a hidden off-switch — and scientists just figured out how to flip it back on.

Quick Take

A protein called Signaling Lymphocytic Activation Molecule Family member 6 (SLAMF6) acts like an internal brake on the immune cells that fight cancer, quietly weakening them from the inside.
A 2026 study published in Nature found that blocking SLAMF6 with an antibody boosted T cell activity and slowed tumor growth in lab models.
The science is promising but still early — no large human trials have confirmed these results yet.
This discovery could help explain why some patients stop responding to today’s best immunotherapy drugs.

Why Cancer Immunotherapy Stops Working for So Many Patients

Immunotherapy changed cancer treatment. Drugs that block proteins like programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) taught the immune system to fight tumors on its own. For some patients, these drugs produced near-miraculous results. But for many others, the drugs worked for a while and then stopped. Tumors came back. T cells — the immune system’s main attack force — seemed to give up. Scientists have spent years trying to understand why.

The answer, at least in part, may involve a protein most people have never heard of. SLAMF6 sits on the surface of T cells. Research published in eLife found that when SLAMF6 is absent, T cells become stronger fighters. They kill tumors more effectively and stay active longer. ^[2] The researchers called SLAMF6 “a constitutive inhibitory immune receptor” — meaning it works as a constant brake, not just an occasional one. That is a big deal, because it means the brake is always on, always slowing the immune response down.

The Hidden Brake That Weakens Your Immune System’s Best Fighters

Here is where it gets interesting. SLAMF6 does not need a tumor cell to trigger it. It activates itself. Two SLAMF6 proteins on neighboring T cells lock together — a process called a cis interaction — and the result is that both T cells get weaker. ^[3] A 2026 Nature study confirmed this mechanism and showed that an antibody designed to break up that interaction “strongly augmented T cell activation” and “reduced the proportions of exhausted T cells.” ^[3] In plain terms: block the handshake, and the T cells wake back up.

The problem SLAMF6 creates is not just a weak T cell today. It also reduces the supply of what researchers call stem-like or progenitor exhausted T cells — the ones capable of renewing themselves and fighting long-term. ^[3] Think of them as the reserve troops. SLAMF6 drains that reserve. That is why patients can respond to immunotherapy at first and then fade. The reserve runs out, and there is nothing left to sustain the attack.

The Evidence Is Strong — But Still Has Gaps That Matter

Separate research from MD Anderson Cancer Center found that blocking SLAMF6 “effectively corrected CD8+ T-cell dysfunction” and reduced tumor burden in cancer models. ^[4] A Nature Communications study showed that in acute myeloid leukemia (AML), a fully human SLAMF6 antibody triggered T cell-mediated killing of leukemia cells in both lab and humanized animal models. ^[5] That is three independent lines of research all pointing in the same direction. That kind of convergence matters in science.

But here is the honest truth: every one of those studies used mice, lab dishes, or humanized animal models — not human patients in a clinical trial. ^[2]^[3]^[5] The Nature abstract itself admits that the role of SLAMF6 “remains ambiguous” because it has both activating and inhibitory effects depending on context. ^[3] The AML study also found “no clear correlation between SLAMF6 status and survival” in patient data sets. ^[5] That does not cancel the excitement, but it does mean the excitement needs to stay calibrated. Science has a long road between “works in mice” and “saves lives in people.”

What Comes Next — and Why It Could Change Cancer Care

The logical next step is a human clinical trial. Researchers would need to test a SLAMF6-blocking antibody in real patients, track whether T cells stay active longer, and measure whether tumors actually shrink and stay gone. They would also need to check for safety. Supercharging the immune system sounds great until it attacks healthy tissue — a real risk with any immune-based therapy. None of that safety data exists yet in the public record. ^[2]^[3]^[5]

Still, the core idea here is sound and the mechanism is specific. SLAMF6 is not some vague target. Researchers identified exactly how it works — T cell to T cell, on the surface, through a physical interaction that can be blocked with a designed antibody. ^[3] That level of precision is what separates a real drug target from a scientific curiosity. If human trials confirm what the lab work shows, SLAMF6 blockade could become a new tool — used alone or alongside existing PD-1/PD-L1 drugs — to help patients who have run out of options. That is worth watching closely, even if the finish line is still a few years away.